Predictive Factors of Tumor Response and Prognostic Factors of Survival during Lung Cancer Chemotherapy

Ray, Patrice; Quantin, Xavier; Grenier, Jean; Pujol, Jean-Louis

doi:10.1046/j.1525-1500.1998.cdoa43.x

Cited by 43 publications

(25 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies suggest the tumor marker utility in prognosis, in both surgical and non-surgical NSCLC. Our results are similar to others that indicate a correlation among tumor markers, specially Cyfra 21.1, and tumor response in patients treated by chemotherapy [33][34][35].…”

Section: Discussionsupporting

confidence: 92%

Integrating concurrent navelbine and cisplatin to hyperfractionated radiotherapy in locally advanced non-small cell lung cancer patients treated with induction and consolidation chemotherapy: feasibility and activity results

et al. 2004

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 92%

Integrating concurrent navelbine and cisplatin to hyperfractionated radiotherapy in locally advanced non-small cell lung cancer patients treated with induction and consolidation chemotherapy: feasibility and activity results

et al. 2004

View full text Add to dashboard Cite

“…Serum LDH levels were independent determinants for OS in advanced NSCLC in some studies [2][3][4][5]15], but not in all studies [24,25]. Hespanhol et al [5] reported that the hazard ratio of abnormal serum LDH levels for death was 1.268 (95 % confidence interval 1.010-1.592) with adjusted p value of 0.04 in multivariate analysis, which was similar in our study.…”

Section: Discussionsupporting

confidence: 85%

“…They found that serum LDH levels, hemoglobin levels, calcium levels, metastatic extents, and chemotherapeutic agents were independent prognostic factors in good PS (PS 0-1) patients. In contrast, Ray et al [25] announced that high serum LDH levels were significant determinants of poor survival in only SCLC but not in NSCLC. The current study explored the clinical relationship between tumor and metastatic characteristics in advanced NSCLC in greater detail, and survival outcomes were analyzed alongside treatment-related factors.…”

Section: Discussionmentioning

confidence: 94%

Serum lactate dehydrogenase levels at presentation in stage IV non-small cell lung cancer: predictive value of metastases and relation to survival outcomes

et al. 2015

View full text Add to dashboard Cite

This study aimed to evaluate the clinical correlations between serum lactate dehydrogenase (LDH) levels and tumor characteristics and to investigate the prognostic impact of serum LDH levels in advanced non-small cell lung cancer (NSCLC). A total of 394 patients were included in the present study between June 2007 and January 2013. All eligible patients had serum LDH levels available before treatment, and whole-body metastatic extent was measured using whole-body metastatic scores, as determined by 18(F)-fludeoxyglucose positron emission tomography scans from 1 to 7 as the sum of each metastatic region. The diagnostic cutoff value for an abnormal serum LDH level was 450 IU/L. The median serum LDH level was 477 IU/L (range, 113-2850), and 224 (56.9 %) patients had abnormal serum LDH levels. The serum LDH levels showed no significant associations with age, gender, histology, tumor differentiation, and smoking history. However, the proportion of patients with abnormal serum LDH levels was statistically significantly higher in the high total metastatic score group (scores 3-7) than in the low total metastatic score group (scores 1-2) (65.3 vs 50.4 %, p = 0.001). In a multivariate survival analysis, age (p = 0.001), gender (p = 0.001), histology (p = 0.003), tumor differentiation (p = 0.001), Eastern Cooperative Oncology Group (ECOG) performance status (p = 0.001), LDH levels (p = 0.046), and treatment factors (p = 0.001) proved to be independent prognostic factors for survival outcomes. The results of this study suggest that the serum LDH levels at presentation may be significantly correlated with whole-body tumor extent and might independently but modestly prognosticate OS in stage IV NSCLC.

show abstract

“…Differences between the curves were tested for significance using one-sided log-rank statistics, and were estimated for noninferiority using the hazard ratio produced by the Cox regression model (Cox and Oakes, 1984). Furthermore, Cox regression models were used to evaluate treatment effects on survival, with adjustment for well-known prognostic factors: stage, PS, gender, weight loss, albumin and LDH (Albain et al, 1991;Espinosa et al, 1995;Paesmans et al, 1995;Ray et al, 1998). Response rates and toxicities were compared using the w 2 test.…”

Section: Discussionmentioning

confidence: 99%

Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer

Negoro

Masuda

Takada³

et al. 2003

Br J Cancer

137

109

View full text Add to dashboard Cite

To determine a standard combination chemotherapy for patients with advanced non-small-cell lung cancer (NSCLC), we conducted a phase III trial of irinotecan (CPT-11) to test the hypotheses that CPT-11+cisplatin is superior to cisplatin+vindesine and that CPT-11 monotherapy is not inferior to cisplatin+vindesine. A total of 398 patients with previously untreated NSCLC were randomised to receive cisplatin+CPT-11 (CPT-P), cisplatin+vindesine (VDS-P) or CPT-11 alone (CPT). In the CPT-P arm, CPT-11 60 mg m À2 was administered on days 1, 8 and 15, and cisplatin 80 mg m À2 was administered on day 1. In the VDS-P arm, cisplatin 80 mg m À2 was administered on day 1, and vindesine 3 mg m À2 was administered on days 1, 8 and 15. In the CPT arm, CPT-11 100 mg m À2 was administered on days 1, 8 and 15. The median survival time was 50.0 weeks for patients on CPT-P, 45.6 weeks for those on VDS-P and 46.0 weeks for those on CPT (P ¼ 0.115, CPT-P vs VDS-P; P ¼ 0.089, CPT vs VDS-P), and the hazard ratio was 0.85 (95% confidence interval (CI): 0.65 -1.11) for CPT-P vs VDS-P and 0.83 (0.64 -1.09) for CPT vs VDS-P. The response rate was 43.7% for patients on CPT-P, 31.7% for those on VDS-P and 20.5% for those on CPT. Major adverse reactions were grade 4 neutropenia observed in 37, 54 and 8% of the patients on CPT-P, VDS-P and CPT, respectively; and grades 3 and 4 diarrhoea observed in 12, 3 and 15% of the patients, respectively. CPT-P therapy produces comparable survival to VDS-P in patients with advanced NSCLC. CPT-11 monotherapy is not inferior to VDS-P in terms of survival. The CPT-11-containing regimen is one of the most efficacious and well tolerated in the treatment of advanced NSCLC.

show abstract

Predictive Factors of Tumor Response and Prognostic Factors of Survival during Lung Cancer Chemotherapy

Cited by 43 publications

References 21 publications

Integrating concurrent navelbine and cisplatin to hyperfractionated radiotherapy in locally advanced non-small cell lung cancer patients treated with induction and consolidation chemotherapy: feasibility and activity results

Integrating concurrent navelbine and cisplatin to hyperfractionated radiotherapy in locally advanced non-small cell lung cancer patients treated with induction and consolidation chemotherapy: feasibility and activity results

Serum lactate dehydrogenase levels at presentation in stage IV non-small cell lung cancer: predictive value of metastases and relation to survival outcomes

Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer

Contact Info

Product

Resources

About